Verici Dx plc (LON:VRCI – Get Free Report) shares were up 14% on Friday . The stock traded as high as GBX 2.93 ($0.04) and last traded at GBX 2.85 ($0.04). Approximately 1,706,122 shares changed hands during mid-day trading, an increase of 75% from the average daily volume of 975,578 shares. The stock had previously closed at GBX 2.50 ($0.03).
Verici Dx Stock Performance
The company has a market cap of £7.59 million, a price-to-earnings ratio of -1.45 and a beta of 1.59. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.64. The business’s 50 day moving average price is GBX 3.16 and its 200-day moving average price is GBX 3.86.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Featured Articles
- Five stocks we like better than Verici Dx
- Insider Trades May Not Tell You What You Think
- MarketBeat Week in Review – 03/24 – 03/28
- Should You Invest in Penny Stocks?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- 3 Warren Buffett Stocks to Buy Now
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
